Compared with lenalidomide (Revlimid) and dexamethasone (Rd) alone, the combination with the addition of daratumumab (Darzalex) (D-Rd) for the treatment of transplant-ineligible, newly diagnosed multiple myeloma was associated with improved patient-reported outcomes (PROs), according to data published in the Journal of Clinical Oncology.
The combination resulted in faster and clinically meaningful improvements in PROs, specifically relating to pain, regardless of depth of treatment response or a patient’s age and baseline ECOG status in the phase III MAIA study (NCT02252172).
“These [health-related quality of life (HRQOL)] improvements were consistent with the clinical benefits of superior [progression-free survival] and deep and durable responses observed with D-Rd and further emphasize the utility of PROs as an adjunct to clinical efficacy in the management of [multiple…
